Immunopeptidomic Profiling of HLA‐A2‐Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens - BSI

470 Weber St. N., Suite 204, Waterloo, ON, Canada N2L 6J2

Call Us: 1-855-885-8288

Home
About Us
- About Us
- News
- Conferences
- Careers
Products
Free Trial
- Download PEAKS Studio
Help & Support
Contact Us

Immunopeptidomic Profiling of HLA‐A2‐Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens

On May 28, 2018May 28, 2018By BSIIn User Publications

Ternette, N., et al. Immunopeptidomic Profiling of HLA‐A2‐Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens. Proteomics. e1700465. 28/5/2018.

Post-Translational Modifications in Polypyrimidine Tract Binding Proteins PTBP1 and PTBP2Proteomic Characterization of a New asymmetric Cellulose Triacetate Membrane for Haemodialysis

Share this post?

Tweet

Recent Posts

HUPO, Adelaide, Australia (September 15-18)

PEAKS X: Label-Free Quantification Webinar (Wednesday, June 26th, 2019)

Online Training

Structural Basis for YjbH Adaptor-Mediated Recognition of Transcription Factor Spx

User Publications

ASMS 2019 & User Meeting

PEAKS Users’ Meeting & ASMS 2019

Protected: PEAKS Training in China 2019

Leave a Reply Cancel Reply

Your email address will not be published.

Name *

Email *

Website

Socials

Facebook
LinkedIn
Twitter
Blogger
YouTube

Solutions

Products & Services
PEAKS Studio
PEAKS Online
PEAKS CMD
PEAKS AB Software

Help

Online Training
Workshops
FAQ
User Manuals
Contact Us

Contact

Bioinformatics Solutions Inc.
470 Weber St. N., Suite 204 Waterloo, ON, Canada N2L 6J2
Phone: 1-855-885-8288
Office Hours: 9:00am - 5:00pm
Privacy Policy

© 2018. Bioinformatics Solutions Inc.